File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/0092623X.2011.606883
- Scopus: eid_2-s2.0-84861307668
- PMID: 22533871
- WOS: WOS:000303565200004
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: A review
Title | Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: A review |
---|---|
Authors | |
Issue Date | 2012 |
Citation | Journal of Sex and Marital Therapy, 2012, v. 38, n. 3, p. 281-301 How to Cite? |
Abstract | There is limited evidence for the management of sexual dysfunction and/or hyperprolactinemia resulting from use of antipsychotics in patients with schizophrenia and spectrum. The aim of this study was to review and describe the strategies for the treatment of antipsychotic-induced sexual dysfunctions and/or hyperprolactinemia. The research was carried out through Medline/PubMed, Cochrane, Lilacs, Embase, and PsycINFO, and it included open labels or randomized clinical trials. The authors found 31 studies: 25 open-label noncontrolled studies and 6 randomized controlled clinical trials. The randomized, double-blind controlled studies that were conducted with adjunctive treatment that showed improvement of sexual dysfunction and/or decrease of prolactin levels were sildenafil and aripiprazole. The medication selegiline and cyproheptadine did not improve sexual function. The switch to quetiapine was demonstrated in 2 randomized controlled studies: 1 showed improvement in the primary outcome and the other did not. This reviewed data have suggested that further well-designed randomized controlled trials are needed to provide evidence for the effects of different strategies to manage sexual dysfunction and/or hyperprolactinaemia resulting from antipsychotics. These trials are necessary in order to have a better compliance and reduce the distress among patients with schizophrenia. Copyright © Taylor & Francis Group, LLC. |
Persistent Identifier | http://hdl.handle.net/10722/289009 |
ISSN | 2021 Impact Factor: 3.099 2020 SCImago Journal Rankings: 0.754 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nunes, Luciana Vargas Alves | - |
dc.contributor.author | Moreira, Hugo Cogo | - |
dc.contributor.author | Razzouk, Denise | - |
dc.contributor.author | Nunes, Sandra Odebrecht Vargas | - |
dc.contributor.author | Mari, Jair De Jesus | - |
dc.date.accessioned | 2020-10-12T08:06:26Z | - |
dc.date.available | 2020-10-12T08:06:26Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Journal of Sex and Marital Therapy, 2012, v. 38, n. 3, p. 281-301 | - |
dc.identifier.issn | 0092-623X | - |
dc.identifier.uri | http://hdl.handle.net/10722/289009 | - |
dc.description.abstract | There is limited evidence for the management of sexual dysfunction and/or hyperprolactinemia resulting from use of antipsychotics in patients with schizophrenia and spectrum. The aim of this study was to review and describe the strategies for the treatment of antipsychotic-induced sexual dysfunctions and/or hyperprolactinemia. The research was carried out through Medline/PubMed, Cochrane, Lilacs, Embase, and PsycINFO, and it included open labels or randomized clinical trials. The authors found 31 studies: 25 open-label noncontrolled studies and 6 randomized controlled clinical trials. The randomized, double-blind controlled studies that were conducted with adjunctive treatment that showed improvement of sexual dysfunction and/or decrease of prolactin levels were sildenafil and aripiprazole. The medication selegiline and cyproheptadine did not improve sexual function. The switch to quetiapine was demonstrated in 2 randomized controlled studies: 1 showed improvement in the primary outcome and the other did not. This reviewed data have suggested that further well-designed randomized controlled trials are needed to provide evidence for the effects of different strategies to manage sexual dysfunction and/or hyperprolactinaemia resulting from antipsychotics. These trials are necessary in order to have a better compliance and reduce the distress among patients with schizophrenia. Copyright © Taylor & Francis Group, LLC. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of Sex and Marital Therapy | - |
dc.title | Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: A review | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1080/0092623X.2011.606883 | - |
dc.identifier.pmid | 22533871 | - |
dc.identifier.scopus | eid_2-s2.0-84861307668 | - |
dc.identifier.volume | 38 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 281 | - |
dc.identifier.epage | 301 | - |
dc.identifier.eissn | 1521-0715 | - |
dc.identifier.isi | WOS:000303565200004 | - |
dc.identifier.f1000 | 716547827 | - |
dc.identifier.issnl | 0092-623X | - |